Cisplatin News and Research

RSS

Natural plant extract reduces cisplatin-induced kidney injury in mice

Acute kidney injury is common in hospitalized patients and rises sharply in intensive care, yet treatment options remain largely supportive.

3 Nov 2026

Common kidney tests underestimate chronic kidney disease in cancer patients

New research indicates that commonly used measures of kidney function largely underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ASN Kidney Week 2026 October 22–25.

23 Oct 2026

ECOG-ACRIN opens trial testing ivonescimab for aggressive bile duct cancer

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it will open a randomized, registration-enabling phase 2/3 clinical trial to evaluate ivonescimab combined with chemotherapy as first-line treatment for patients with advanced biliary tract cancer (BTC).

21 Oct 2026

Local DNA motion remains nearly constant during cell interphase

Human genomic DNA is wrapped around core histone proteins to form nucleosomes, the fundamental units of chromatin.

14 Oct 2026

Weekly cisplatin fails to reduce acute toxicity in advanced head and neck cancer

Physicians typically use either a higher dose of cisplatin given every three weeks or a lower dose given weekly in combination with radiation to treat locally advanced head and neck cancer.

29 Sep 2026

UCLA researchers present new radiation advances at ASTRO 2026

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share new research and clinical trial findings at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on new treatment approaches for prostate, bile duct and head and neck cancers, personalized radiation therapy based on genetic risk, and advances in targeted radiation and radioligand therapy designed to improve cancer control while limiting treatment side effects.

25 Sep 2026

Shortages of crucial cancer medications continue to impact US healthcare

Today, the National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-published updated data on the current impact of generic cancer medication shortages in the United States.

10 Sep 2026

Psilocybin protects sensory nerves from chemotherapy damage in preclinical study

In mouse models, prophylactic psilocybin prevented or reduced multiple features of chemotherapy-induced peripheral neuropathy, with cycle-matched dosing sustaining protection during repeated cisplatin exposure without measurably affecting tumor growth. Experiments in human-derived sensory neurons and ex vivo peripheral nerves linked the effect to 5-HT2A-dependent preservation of mitochondrial trafficking and local axonal energy supply, while a nonhallucinogenic 5-HT2A agonist reproduced protection against mechanical hypersensitivity.

6 Sep 2026

Lab-grown mini tumors help scientists predict breast cancer treatment success

Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid testing on lab-grown mini tumors.

11 Aug 2026

Autophagy modulation emerges as a strategy against cisplatin-resistant gastric cancer

Drug resistance remains one of the greatest obstacles to successful treatment of gastric cancer, limiting the long-term effectiveness of the widely used chemotherapy drug cisplatin.

6 Aug 2026

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment

A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC).

6 Aug 2026

Study identifies a novel direct drug target for head and neck squamous cell carcinoma

Chemotherapy remains a cornerstone of treatment for head and neck cancers, the seventh-most common cancer type worldwide.

6 Aug 2026

Excess EXO1 protein may drive cancer DNA damage and treatment response

When it comes to cancer, tumor suppressor genes are usually thought of as the "good guys." These genes make proteins that protect and repair DNA in cells.

21 May 2026

New mechanism to enhance precision in cancer drug development

Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from breaking when cells copy damaged genetic material, a discovery that could affect how certain cancer drugs are developed.

15 May 2026

Damon Runyon supports young scientists driving cancer research innovation

The Damon Runyon Cancer Research Foundation has named 13 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

11 Apr 2026

Clusterin inhibition offers new hope for treating cervical gastric-type adenocarcinoma

Gastric-type adenocarcinoma (GAS) is one of the most aggressive non-human papillomavirus (HPV)-associated cervical adenocarcinomas and remains especially difficult to diagnose and treat.

8 Apr 2026

Study reveals CAR T approach for hard-to-treat solid tumors

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma.

30 Mar 2026

DNA nanomachine strategy reverses chemoresistance in small cell lung cancer

Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a novel DNA nanomachine-based drug delivery and release strategy aimed at overcoming chemoresistance in small cell lung cancer (SCLC).

6 Mar 2026

Blocking growth hormone receptor may improve treatment response in lung cancer

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

2 Mar 2026

Study reveals long-term health risks after chemotherapy for testicular cancer

A large, multi-center study recently published online in the Journal of the National Comprehensive Cancer Network (JNCCN) provides new insight into the long-term health effects of contemporary chemotherapy regimens used to treat testicular cancer, highlighting differences in renal function, cardiovascular risk, and the overall burden of chronic health conditions among survivors.

19 Feb 2026